Find Trials Near
Speak with a clinical trials expert
Have multiple conditions? Click here

Parkinsons Disease Clinical Trials

New Clinical Trials for Parkinson’s Disease

Enroll in a Clinical Trial for Parkinson's DiseaseParkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. Although we know what happens buy tramadol no prescription how to buy tramadol online generic tramadol online that causes Parkinson’s disease, Parkinson’s disease clinical research has a long way to go to figure out why it happens and what we can do to prevent it from happening.

Current Parkinson’s disease clinical trials are studying Parkinson’s disease in animals, gene therapy, neuroprotective treatments, and neural transplantation priligy generic visit us priligy pharmacy . There are ongoing Parkinson’s disease clinical trials being conducted to learn more about this debilitating disease.

What is Parkinson’s Disease?

Parkinson’s disease (PD) is a degenerative disorder of the central nervous system that over time leads to a decrease in motor skills and mental capacity ativan pharmacy buy ativan mexico cheap ativan online . The disease is characterized by tremors mainly in the arms. In its advanced stages patients often develop dementia and have trouble performing everyday tasks buy valium usa buy valium online usa valium online usa . It is also called primary Parkinsonism or idiopathic Parkinson’s disease. It was first documented in 1817 visit us buy ambien online canada ambien canada . Parkinson’s disease is caused by dopamine in the brain not forming and acting as it should. It is not known why this happens. There are indications that it is a genetic disease and links have been found between Parkinson’s disease and exposure to pesticides.

Parkinson’s Disease Treatments

Treating Parkinson’s disease is usually done through a combination of methods including diet, medications and exercise cheapest valum order valum america valum online usa . Medications that may be prescribed include levodopa, dopamine agonists and MAO-B inhibitors. Physical rehabilitation and exercise can help put off the decline of motor skills and speech therapy has proven helpful here generic ultram information cod ultram . Exercise also helps maintain muscle strength, motor skills and improves constipation (another symptom of Parkinson’s disease). Since this disease progresses treating Parkinson’s disease needs to occur in stages. Medications that are effective at the beginning need to be monitored as the disease progresses. They may become ineffective or start to cause harmful side effects.

NEW Effect on Parkinson's Disease After Therapeutic Induction of CranioSacral Integrated Therapy

Ann Arbor
Michigan
48104
Age: 18 - Any
Conditions: Parkinsons Disease

NEW AADC Gene Therapy for Parkinson's Disease

San Francisco
California
94122
Age: 40 - 70
Conditions: Parkinsons Disease

NEW Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

West Bloomfield
Michigan
Age: 35 - 75
Conditions: Parkinsons Disease

NEW Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

Golden valley
Minnesota
Age: 35 - 75
Conditions: Parkinsons Disease

NEW Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

New Brunswick
New Jersey
Age: 35 - 75
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Fountain Valley
California
92708
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Englewood
Colorado
80113
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Danbury
Connecticut
06810
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Boca Raton
Florida
33486
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Kansas City
Kansas
66160
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Baltimore
Maryland
21201
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Boston
Massachusetts
02215
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

West Bloomfield
Michigan
48322
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Minneapolis
Minnesota
55414
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

St. Louis
Missouri
63110
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Asheville
North Carolina
28806
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Philadelphia
Pennsylvania
19107
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Charleston
South Carolina
29401
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Seattle
Washington
98101
Age: 30 - Any
Conditions: Parkinsons Disease

NEW A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Los Angeles
California
90048
Age: 30 - Any
Conditions: Parkinsons Disease
Return to Search Results
Updating search results
One moment     loading
BROWSE CLINICAL TRIALS BY STATE
Alabama - Alaska - Arizona - Arkansas - California - Colorado - Connecticut - Delaware - Washington DC - Florida - Georgia - Hawaii - Idaho - Illinois - Indiana - Iowa - Kansas - Kentucky - Louisiana - Maine - Maryland - Massachusetts - Michigan - Minnesota - Mississippi - Missouri - Montana - Nebraska - Nevada - New Hampshire - New Jersey - New Mexico - New York - North Carolina - North Dakota - Ohio - Oklahoma - Oregon - Pennsylvania - Rhode Island - South Carolina - South Dakota - Tennessee - Texas - Utah - Vermont - Virginia - Washington - West Virginia - Wisconsin - Wyoming
Copyright 2014 Clinical Trials GPS | All Rights Reserved



Forgot Password?